Phase II KarMMa: Idecabtagene Vicleucel for R/R Multiple Myeloma

May 29-31, 2020; Online at meetings.asco.org/am
Idecabtagene vicleucel therapy resulted in CR/sCR responses in one third of patients with heavily pretreated R/R MM with durability approaching 2 years.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

Download these expert-selected slides on treatments for early and later-stage relapsed/refractory multiple myeloma

Sagar Lonial, MD Thomas G. Martin, MD Released: October 6, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022

Download these expert-selected slides on later-stage relapsed/refractory myeloma to help manage your patients, from Clinical Care Options (CCO).

Paul G. Richardson, MD Released: September 22, 2022

See key clinical insights fast, with this short slideset from CCO on relapsed/refractory myeloma, from Clinical Care Options (CCO).

Natalie S. Callander, MD Noopur Raje, MD Paul G. Richardson, MD Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings